MFS Municipal Income Trust (NYSE:MFM) versus VanEck Biotech ETF (NASDAQ:BBH) Head-To-Head Analysis

MFS Municipal Income Trust (NYSE:MFM) and VanEck Biotech ETF (NASDAQ:BBH) are both small-cap finance companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, risk, valuation, dividends and profitability.

Insider and Institutional Ownership

32.0% of VanEck Biotech ETF shares are owned by institutional investors. 0.8% of MFS Municipal Income Trust shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility and Risk

MFS Municipal Income Trust has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500. Comparatively, VanEck Biotech ETF has a beta of 0.85, indicating that its share price is 15% less volatile than the S&P 500.

Valuation & Earnings

This table compares MFS Municipal Income Trust and VanEck Biotech ETF”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MFS Municipal Income Trust	$46.87 million	5.40	N/A	N/A	N/A
VanEck Biotech ETF	N/A	N/A	N/A	N/A	N/A

Dividends

MFS Municipal Income Trust pays an annual dividend of $0.25 per share and has a dividend yield of 4.8%. VanEck Biotech ETF pays an annual dividend of $1.25 per share and has a dividend yield of 0.8%.

Profitability

This table compares MFS Municipal Income Trust and VanEck Biotech ETF’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MFS Municipal Income Trust	N/A	N/A	N/A
VanEck Biotech ETF	N/A	N/A	N/A

Analyst Recommendations

This is a summary of current ratings and recommmendations for MFS Municipal Income Trust and VanEck Biotech ETF, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MFS Municipal Income Trust	0	0	0	0	0.00
VanEck Biotech ETF	0	8	4	0	2.65

VanEck Biotech ETF has a consensus target price of $155.32, suggesting a potential upside of 0.00%. Given VanEck Biotech ETF’s stronger consensus rating and higher probable upside, analysts plainly believe VanEck Biotech ETF is more favorable than MFS Municipal Income Trust.

Summary

VanEck Biotech ETF beats MFS Municipal Income Trust on 5 of the 8 factors compared between the two stocks.

About MFS Municipal Income Trust

MFS Municipal Income Trust is a close ended fixed income mutual fund launched and managed by Massachusetts Financial Services Company. The fund invests in fixed income markets of the United States. It primarily invests in tax-exempt bonds and tax-exempt notes. The fund benchmarks the performance of its portfolio against Barclays Municipal Bond Index. MFS Municipal Income Trust was founded in November 25, 1986 and and is domiciled in United States.

About VanEck Biotech ETF

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.